Cardiol Therapeutics Inc (NASDAQ: CRDL) on Tuesday, plunged -7.82% from the previous trading day, before settling in for the closing price of $1.79. Within the past 52 weeks, CRDL’s price has moved between $0.79 and $3.12.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -20.00% annually for the last half of the decade. The company achieved an average annual earnings per share of -13.78%. With a float of $66.17 million, this company’s outstanding shares have now reached $69.88 million.
In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Cardiol Therapeutics Inc (CRDL) Insider and Institutional Ownership
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Cardiol Therapeutics Inc is 5.31%, while institutional ownership is 7.75%.
Cardiol Therapeutics Inc (CRDL) Latest Financial update
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.12 earnings per share (EPS) for the period topping the consensus outlook (set at -0.12) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -13.78% per share during the next fiscal year.
Cardiol Therapeutics Inc (NASDAQ: CRDL) Trading Performance Indicators
Cardiol Therapeutics Inc (CRDL) is currently performing well based on its current performance indicators. A quick ratio of 2.49 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.39, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.36 in one year’s time.
Technical Analysis of Cardiol Therapeutics Inc (CRDL)
Let’s dig in a bit further. During the last 5-days, its volume was 0.59 million. That was better than the volume of 0.42 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 14.59%. Additionally, its Average True Range was 0.14.
During the past 100 days, Cardiol Therapeutics Inc’s (CRDL) raw stochastic average was set at 8.41%, which indicates a significant increase from 6.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.41% in the past 14 days, which was lower than the 59.49% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9838, while its 200-day Moving Average is $1.9532. However, in the short run, Cardiol Therapeutics Inc’s stock first resistance to watch stands at $1.7633. Second resistance stands at $1.8767. The third major resistance level sits at $1.9533. If the price goes on to break the first support level at $1.5733, it is likely to go to the next support level at $1.4967. The third support level lies at $1.3833 if the price breaches the second support level.
Cardiol Therapeutics Inc (NASDAQ: CRDL) Key Stats
Market capitalization of the company is 186.87 million based on 81,603K outstanding shares. Right now, sales total 0 K and income totals -20,840 K. The company made 0 K in profit during its latest quarter, and -9,330 K in sales during its previous quarter.
